Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth (VP)
A Pilot Study of Vaginal Progesterone to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
This PHASE4 trial investigates PreTerm Birth and is currently completed. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 7 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Apr 2019 — Mar 2020 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- University of North Carolina, Chapel Hill
For direct contact, visit the study record on ClinicalTrials.gov .